InterAx Biotech and Boehringer Ingelheim collaborate for enabling the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform
Biberach, Germany and Villigen, Switzerland – 6th of August 2019
InterAx Biotech AG announced today that it has entered an agreement with Boehringer Ingelheim to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform. InterAx and Boehringer will collaborate to characterize drug candidates for an undisclosed target. “We are looking forward to combining our unique technology with the expertise of Boehringer Ingelheim to identify compounds with superior biological properties for one of Boehringer’s target receptors”, says Maria Waldhoer, CSO at InterAx. Financial terms of the partnership were not disclosed.
InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company is uniquely positioned to assist drug candidate design and selection for G protein-coupled receptors in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in-house derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms.